AGWCA
GMAB icon

Annis Gardner Whiting Capital Advisors’s Genmab GMAB Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-362
Closed -$11.2K – 1357
2025
Q4 		$11.2K Buy
+362
New +$11.3K ﹤0.01% 758
2025
Q3 		– Sell
-122
Closed -$2.52K – 1287
2025
Q2 		$2.52K Buy
+122
New +$2.5K ﹤0.01% 928

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's GMAB Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Genmab (GMAB) in Q1 2026, closing a stake of 362 shares — an estimated $11.2K sold.

Annis Gardner Whiting Capital Advisors first reported a position in GMAB in Q2 2025 and held it in 2 quarters. The position peaked at $11.2K in Q4 2025. 275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 362 Genmab shares in Q1 2026, an estimated $11.2K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Genmab in Q2 2025 and held it in 2 quarters.
  • Annis Gardner Whiting Capital Advisors's Genmab position peaked at $11.2K in Q4 2025.
  • 275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.